NCT02972658 · Phase 3 · TERMINATED
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It was an extension of a larger study called AMARANTH. Phase 3 means the drug was being evaluated for real-world effectiveness in a large group — but note that lanabecestat's development program was halted in 2018 after trials failed to show benefit.
You may qualify if
- Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed-start I8D-MC-AZFD.
You're excluded if
- Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2019-12-03